WO2006015195A1 - Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase - Google Patents

Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase Download PDF

Info

Publication number
WO2006015195A1
WO2006015195A1 PCT/US2005/026945 US2005026945W WO2006015195A1 WO 2006015195 A1 WO2006015195 A1 WO 2006015195A1 US 2005026945 W US2005026945 W US 2005026945W WO 2006015195 A1 WO2006015195 A1 WO 2006015195A1
Authority
WO
WIPO (PCT)
Prior art keywords
pgd2
compound
levels
mammalian cell
cells
Prior art date
Application number
PCT/US2005/026945
Other languages
French (fr)
Other versions
WO2006015195A8 (en
Inventor
Yang Cao
Jeffrey S. Sabol
Stephen Ayers
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05781699T priority Critical patent/DK1778860T3/en
Priority to US11/569,146 priority patent/US20070259384A1/en
Priority to AU2005267920A priority patent/AU2005267920A1/en
Priority to EP05781699A priority patent/EP1778860B1/en
Priority to JP2007523838A priority patent/JP2008507980A/en
Priority to MX2007000043A priority patent/MX2007000043A/en
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Priority to DE602005004420T priority patent/DE602005004420T2/en
Priority to CA002575523A priority patent/CA2575523A1/en
Priority to BRPI0512645-2A priority patent/BRPI0512645A/en
Publication of WO2006015195A1 publication Critical patent/WO2006015195A1/en
Publication of WO2006015195A8 publication Critical patent/WO2006015195A8/en
Priority to IL180837A priority patent/IL180837A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Definitions

  • the present invention relates to a novel and useful method for assaying compounds and agents for their ability to decrease or inhibit the activity of hematopoietic prostaglandin D2 synthase (hPGDS). Specifically, the present invention relates to assays for measuring the potency, specificity and toxicity of hPGDS inhibitors.
  • hPGDS hematopoietic prostaglandin D2 synthase
  • Prostaglandins are a class of eicosanoids that have diverse biological effects. Prostaglandins have been shown to have pharmacological effects on the cardiovascular system, platelet aggregation, effects on smooth muscle thereby effecting the gastrointestinal system, kidney function and urine formation, effects on the central nervous system, endocrine system, effects on metabolism and play a critical role in inflammation and immune responses. Thus, prostaglandins represent the potential to have broad therapeutic utility. Prostaglandins are synthesized from arachidonic acid, and possess a five-membered ring of carbon atoms that had formed part of the chain of arachidonic acid. Typically, prostaglandins act locally, i.e., near the site of their synthesis.
  • Prostaglandin D2 is the major prostanoid produced by activated mast cells in response to antigen challenge, which is a major mediator of airway allergic disorders. In particular, it causes, among other things, bronchoconstriction, bronchial hyper-responsiveness, nasal congestion and eosinophil and TH2 cell infiltration. It is also thought that released PGD2 from antigen-stimulated mast cells and basophils elicit immediate hypersensitivity, airway inflammation or remodeling in asthma.
  • the enzyme prostaglandin D synthase catalyzes the conversion of prostaglandin H2 (PGH2) into PGD2.
  • PGD2 synthases Two types are known.- The first is a lipocalin-type (L-PGDS) found mainly in the central nervous system, and the second is hematopoietic PGDS (hPGDS), which is found primarily in peripheral tissues. L-PGDS is glutathione (GSH)-independent while hPGDS is GSH-dependent. Furthermore, there is very little structural homology between L-PGDS and hPGDS. Since PGD2 plays an important role in inflammation, efforts have been made to develop assays to screen for compounds that may inhibit their production.
  • inhibitors of PGD2 synthesis may be valuable in the treatment of allergic rhinitis, asthma and possibly chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the therapeutic application may also be extended to the treatment of multiple sclerosis, Alzheimer's disease and disorders resulting from ischemia-reperfusion injury, brain tumor and therapeutic applications in biological processes modulated by prostaglandins.
  • HPLC high pressure liquid chromatography
  • ELISA enzyme-linked immunosorbent assays
  • EIA enzyme immunoassays
  • RIA radioimmunoassays
  • the present invention establishes a single cell-based assay to evaluate potency, specificity, and cytotoxicity simultaneously for hPGDS modulators.
  • Compounds that modulate the activity of hPGDS provide novel therapeutic approaches for the treatment of inflammation and pharmacological manipulation of immune responses.
  • the assay design is suitable for use in any mammalian cell line in which hPGD2 is expressed such as mast cells, antigen-presenting cells, megakaryocytes and Th2 lymphocytes.
  • the mammalian cells are treated with a stimulatory molecule that enhances arachidonic acid release.
  • Molecules contemplated in the present invention are calcium ionophores such as A23187, ionomycin, phorbel esters, growth factors, cytokines, tumor promoters, or a calcium channel mobilizer molecules such as BAY K-8644.
  • arachidonic acid may be directly added to the cells.
  • Cells used to screen for compounds that modulate hPGDS are treated with the test compound and a stimulatory molecule to induce arachidonic acid release.
  • PGD2 production levels are measured in the presence of test compound and compared with PGD2 levels without test compound pre-treatment.
  • the present invention provides for specificity and cytotoxicity measurements all in the same cell- based assay system.
  • test compound specifically inhibits hPGDS activity, it will generate an IC50 on PGD2 that is significantly lower than that on PGE2. In contrast, if the test compound is non-specific or cytotoxic, it will generate similar IC50 values on PGD2 and PGE2. Additional cytotoxicity testing can be used to determine whether these values are due to the toxicity of the test compound or non-specific inhibition of prostanoid synthesis.
  • FIG 1 shows the results of the cell-based assay distinguishing between specific and non-specific PGD2 inhibitors.
  • Compound A000050350 specifically inhibits PGD2 production in RBL cells whereas compound AOOO 127348 non-specifically inhibits both PGD2 and PGE2 production in RBL cells.
  • FIG 2 is a graph representing the evaluation of cytotoxicity by measuring cell proliferation of rat basophilic leukemia (RBL) cells treated with several concentrations of PGDS test compounds using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay.
  • RBL basophilic leukemia
  • the present invention relates to a cell-based assay for screening compounds that modulate hematopoietic PGD2 synthase (hPGDS).
  • the assay evaluates potency, specificity and toxicity of test compounds in living cells.
  • the present invention allows for the identification of inhibitor compounds that may be used as drugs to treat many inflammatory diseases including but not limited to asthma, allergic rhinitis, COPD, multiple sclerosis, Alzheimer's disease and other disorders resulting from ischemia-reperfusion injury.
  • the present invention generally relates to a cell based assay, which is used to measure potency, specificity and cytotoxicity of test compounds that modulate hPGDS activity within a single cell based assay. Measurements can be performed quickly and can be scaled up to test many different compounds simultaneously.
  • Examples include small molecular weight chemical molecules, libraries of synthetic low molecular compounds, purified proteins, expression products of gene libraries, synthetic peptide libraries, cell extracts and culture supernatants.
  • mammalian cell line may be used in the present invention as long as the mammalian cell line expresses hPGDS.
  • Examples include, but are not limited to, mast cells, antigen-presenting cells, megakaryocytes and Th2 lymphocytes.
  • mammalian cell lines may be used such as rat basophilic leukemia (RBL).
  • RBL rat basophilic leukemia
  • Primary mast cells in different species such as human and mouse, or T cell subtypes in different species are the additional examples.
  • Cells engineered to express or overexpress hPGDS or modified hPGDS are contemplated by the present invention.
  • the chosen mammalian cells are treated with a stimulatory molecule that enhances arachidonic acid release.
  • Molecules contemplated for use in the present invention are calcium ionophores such as A23187, ionomycin, phorbel esters, growth factors, cytokines, tumor promoters, and calcium channel mobilizer molecules such as BAY K-8644.
  • arachidonic acid may be directly added to the chosen mammalian cells.
  • cells are treated with a test compound followed by the addition of a stimulatory molecule to enhance arachidonic acid release. Levels of PGD2 production are measured in cells treated with the stimulatory molecule and various concentrations of test compounds.
  • the present invention also provides in the same cell-based assay the ability to measure specificity and cytotoxicity. This is designed by evaluating a second readout of prostanoid production, for example, levels of PGE2, in the cell supernatant. If a test compound specifically inhibits hPGDS activity, it will generate an IC50 on PGD2 that is significantly lower than that on PGE2. In contrast, if the test compound is non-specific or cytotoxic, it will generate similar IC50 values for both PGD2 and PGE2.
  • an additional cytotoxicity assay may be set up subsequently using the same samples as in the cell-based assay, or separately using the same conditions as the cell-based assay described above.
  • a finding of inhibition of cell proliferation is considered a measurement of off-target activity of the tested compound.
  • Cytotoxicity assays that may be used in the present invention include but are not limited to assays such as MTS, MTT and LDH assays, all commercially available from Promega, for example.
  • the ability of a compound to modulate levels of PGD2 is determined, not just by taking measurements in the presence and absence of the inhibitor compound, but also at various concentrations thereof. By taking measurements at various compound concentrations, it is possible to calculate certain features, such as its IC50.
  • An IC50 is defined as the concentration at which the compound produces 50% inhibition.
  • the assay of the present invention is easily amendable to assay for compounds that stimulate PGD2 production by using a sub-threshold amount of stimulatory molecule or no stimulatory molecule.
  • the assay of the present invention may also be conducted as a single point assay evaluating the inhibition of compound on PGD2 and PGE2 production using only one concentration of test compound. Both single point screening and IC50 determinations are amenable to high throughput screening.
  • High throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkington, Mass.; Air Technical Industries, Mentor, Ohio; Beckman Instruments, Inc. Fullerton, Calif.; Precision Systems, Inc., Natick, Mass., etc.). These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final reading of the samples in detector(s) appropriate for the assay.
  • These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for the various high throughput assays. Methods of measuring concentrations of PGD2 and PGE2 are well known in the art.
  • Examples include high pressure liquid chromatography (HPLC), gas chromatography mass spectrometry (GC-MS), enzyme-linked immunosorbent assay (ELISA), also known as enzyme immunoassay (EIA), radioimmunoassay (RIAs), and fluorescence polarization (FP).
  • HPLC high pressure liquid chromatography
  • GC-MS gas chromatography mass spectrometry
  • ELISA enzyme-linked immunosorbent assay
  • EIA enzyme immunoassay
  • RIAs radioimmunoassay
  • FP fluorescence polarization
  • the scintillation proximity assay may also be useful in measuring PGD2 and PGE2 levels.
  • EXAMPLE 1 CELL TREATMENT WITH CALCIUM IONOPHORE AND INCUBATION WITH TEST AND CONTROL COMPOUNDS
  • RBL-2H3 cells obtained from the American Tissue Culture Center
  • MEM media Gibco 11095-080
  • fetal bovine serum fetal bovine serum
  • penicillin and streptomycin to a single-cell suspension.
  • RBL cells are plated at 2x10 4 cells/well in 96 well plates. The plates are incubated overnight at 37 0 C.
  • HBSS buffer (Gibco/Invitrogen 14025-092) is diluted with DMSO (Sigma D-8779) equivalent to the highest concentration of DMSO contained in the reference or test compound.
  • DMSO Sigma D-8779
  • the compound plate(s) and reference control are thawed and mixed well before use.
  • a COX-I inhibitor SC560 was used as a reference and purchased from Cayman Chemical.
  • Test compound and reference SC560 dilutions are made with a Costar (3960 or equivalent) assay block according to the EIA template shown below.
  • Controls 1, 2, 5 and 6 are positive controls containing calcium ionophore without compound.
  • Controls 3, 4, 7 and 8 are negative controls without calcium ionophore or compound.
  • Test compounds were diluted as follows: Add 1 ml of HBSS (without DMSO) to assay block wells A4-A10 [30 uM]. Add 620 ul of HBSS w/ 0.3% DMSO to wells B4-B10 through H4-H10. Add 3 ul of compound stock [10 mM] to 30 uM wells. Mix well. Add 310 ul from row A [30 uM] to row B [10 uM]. Mix well. Continue diluting as above, to generate the following concentrations [30, 10, 3.3, 1.1, 0.37, 0.12, 0.04, and 0.014 uM]. The reference SC560 was diluted as follows: Add 1 ml of HBSS (without DMSO) to well All.
  • EXAMPLE 2 QUANTIFICATION OF PROSTAGLANDIN D2 LEVELS: ENZYME IMMUNOASSAY
  • concentration of PGD2 was measured using an enzyme immunoassay (EIA).
  • EIAs for measuring PGD2 are available commercially.
  • PGD2 EIA kits are available from Cayman Chemical. This assay is based on the competition between PGD2-methoxime (MOX) and a PGD2-MOX-acetyleholinesterase (AchE) conjugate (PGD2-M0X tracer) for a limited number of PGD2-M0X- specific rabbit antiserum binding sites.
  • MOX PGD2-methoxime
  • AchE PGD2-MOX-acetyleholinesterase
  • the concentration of the PGD2-M0X tracer is held constant while the concentration of PGD2-MOX varies, the amount of PGD2-M0X tracer that is able to bind to the rabbit antiserum will be inversely proportional to the concentration of PGD2-M0X in the well.
  • This rabbit antiserum-PGD2- MOX complex binds to the mouse monoclonal anti-rabbit IgG that has been previously attached to the well. After washing the plate, Ellman's Reagent (which contains the substrate to AchE) is added to the well. The enzymatic product has a distinct yellow color, which absorbs strongly at 412 nm. The intensity of this color is proportional to the amount of
  • PGD2-MOX tracer bound to the well which is inversely proportional to the amount of free PGD2-MOX present in the well during the incubation.
  • EIA and wash buffers were made according to the commercial instructions. Samples were prepared according to the previous example. Since prostaglandin levels may vary, the supernatants are diluted with EIA buffer to yield prostaglandin levels within the linear range of the standard curve. Commonly used PGD2 dilutions are 1 : 12.5.
  • the methyl oximating reagent, PGD2-M0X Express EIA standard, PGD2-M0X AchE Express Tracer, PGD2-M0X Express Antiserum and PGD2-M0X Express EIA Methoximating control were prepared according to the manufacturer's instructions. The assay was performed according to the manufacturer's instructions and the plates were read at a wavelength of 412 nm.
  • an IC50 of the compound may be generated by conducting a semi-log plot of the prostaglandin level versus log scale of the compound concentration. This assay can also be conducted as a single point assay evaluating the inhibition of compound on PGD2 production using only one concentration of compound.
  • the PGE2 concentrations were measured using an enzyme immunoassay (EIA).
  • EIAs for measuring PGE2 are available commercially.
  • a PGE2 EIA kit is available from Assay Designs.
  • the PGE2 EIA employs a mouse monoclonal antibody specific for PGE2.
  • the free PGE2 in solution competes with a known amount of PGE2 tracer to bind a limited amount of the anti-PGE2 antibody.
  • the PGE2 tracer is a conjugate of PGE2 and acetylcholinesterase.
  • the anti-PGE2 antibody is then fixed using a goat anti-mouse Ig antibody.
  • the fixed antibody is then developed with Ellman's Reagent, which contains the substrate for acetylcholinesterase.
  • the product produced by this reaction has a yellow color, and absorbs strongly at 412 nm. If there is a high concentration of PGE2, the PGE2 will outcompete the tracer and the resulting sample will have a weak absorbance at 412 nm. Conversely, if there is a low concentration of PGE2, the tracer will outcompete the PGE2 and the resulting sample will have a strong absorbance at 412 nm. In performing this assay, the absorbance at 412 nm was compared to a standard of absorbances at known concentrations of PGE2.
  • This assay may be easily converted to automated format by one skilled in the art by using a Zymark SciClone Deck, for example.
  • RBL cells were treated with the PGDS compounds for 45 min under the same condition as in the cell-based assay except no A23187 was added.
  • the potential cytotoxicity was determined with the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI Cat# G3582). The assay was carried out following the manufacturer's instruction.
  • MTS CellTiter 96 Aqueous One Solution Cell Proliferation Assay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to a novel and useful method for assaying compounds and agents for their ability to decrease or inhibit the activity of hematopoietic prostaglandin D2 synthase (hPGDS). Specifically, the present invention relates to assays for measuring the potency, specificity and toxicity of hPGDS inhibitors.

Description

METHODS FORDETERMINING THE POTENCY, SPECIFICITY, AND TOXICITY OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
FIELD OF THE INVENTION
The present invention relates to a novel and useful method for assaying compounds and agents for their ability to decrease or inhibit the activity of hematopoietic prostaglandin D2 synthase (hPGDS). Specifically, the present invention relates to assays for measuring the potency, specificity and toxicity of hPGDS inhibitors.
BACKGROUND OF THE INVENTION
Prostaglandins are a class of eicosanoids that have diverse biological effects. Prostaglandins have been shown to have pharmacological effects on the cardiovascular system, platelet aggregation, effects on smooth muscle thereby effecting the gastrointestinal system, kidney function and urine formation, effects on the central nervous system, endocrine system, effects on metabolism and play a critical role in inflammation and immune responses. Thus, prostaglandins represent the potential to have broad therapeutic utility. Prostaglandins are synthesized from arachidonic acid, and possess a five-membered ring of carbon atoms that had formed part of the chain of arachidonic acid. Typically, prostaglandins act locally, i.e., near the site of their synthesis.
Prostaglandin D2 (PGD2) is the major prostanoid produced by activated mast cells in response to antigen challenge, which is a major mediator of airway allergic disorders. In particular, it causes, among other things, bronchoconstriction, bronchial hyper-responsiveness, nasal congestion and eosinophil and TH2 cell infiltration. It is also thought that released PGD2 from antigen-stimulated mast cells and basophils elicit immediate hypersensitivity, airway inflammation or remodeling in asthma.
The enzyme prostaglandin D synthase (PGDS) catalyzes the conversion of prostaglandin H2 (PGH2) into PGD2. Two types of PGD2 synthases are known.- The first is a lipocalin-type (L-PGDS) found mainly in the central nervous system, and the second is hematopoietic PGDS (hPGDS), which is found primarily in peripheral tissues. L-PGDS is glutathione (GSH)-independent while hPGDS is GSH-dependent. Furthermore, there is very little structural homology between L-PGDS and hPGDS. Since PGD2 plays an important role in inflammation, efforts have been made to develop assays to screen for compounds that may inhibit their production. In particular, inhibitors of PGD2 synthesis may be valuable in the treatment of allergic rhinitis, asthma and possibly chronic obstructive pulmonary disease (COPD). The therapeutic application may also be extended to the treatment of multiple sclerosis, Alzheimer's disease and disorders resulting from ischemia-reperfusion injury, brain tumor and therapeutic applications in biological processes modulated by prostaglandins.
Techniques such as high pressure liquid chromatography (HPLC), enzyme-linked immunosorbent assays (ELISA), also known as enzyme immunoassays (EIA), or radioimmunoassays (RIA) are used to quantify the production of PGD2 in order to determine a compound's or agent's ability to decrease, inhibit, enhance or modulate the production of PGD2.
In the past, assessments of potency, specificity and toxicity have been separated into different experimental paradigms. Moreover, specificity determinations were more feasible in biochemical assays that in many cases could not mimic the complex biological conditions existing in cells. Thus, it is desirable to design a cell based assay that measures potency, specificity and toxicity of PGDS modulators from the same experimental sample. Such a design would shorten the steps that usually require secondary screening and provide information that is more closely relevant to the cell conditions in vivo.
BRIEF SUMMARY OF THE INVENTION
The present invention establishes a single cell-based assay to evaluate potency, specificity, and cytotoxicity simultaneously for hPGDS modulators. Compounds that modulate the activity of hPGDS provide novel therapeutic approaches for the treatment of inflammation and pharmacological manipulation of immune responses. The assay design is suitable for use in any mammalian cell line in which hPGD2 is expressed such as mast cells, antigen-presenting cells, megakaryocytes and Th2 lymphocytes. In the present invention, the mammalian cells are treated with a stimulatory molecule that enhances arachidonic acid release. Molecules contemplated in the present invention are calcium ionophores such as A23187, ionomycin, phorbel esters, growth factors, cytokines, tumor promoters, or a calcium channel mobilizer molecules such as BAY K-8644. In one particular embodiment, arachidonic acid may be directly added to the cells. Cells used to screen for compounds that modulate hPGDS are treated with the test compound and a stimulatory molecule to induce arachidonic acid release. PGD2 production levels are measured in the presence of test compound and compared with PGD2 levels without test compound pre-treatment. In addition to measuring the potency of a test compound, the present invention provides for specificity and cytotoxicity measurements all in the same cell- based assay system. This is designed by evaluating a second readout for PGE2. For example, if a test compound specifically inhibits hPGDS activity, it will generate an IC50 on PGD2 that is significantly lower than that on PGE2. In contrast, if the test compound is non-specific or cytotoxic, it will generate similar IC50 values on PGD2 and PGE2. Additional cytotoxicity testing can be used to determine whether these values are due to the toxicity of the test compound or non-specific inhibition of prostanoid synthesis.
The above aspects and other aspects, features, and advantages of the present invention will be better understood from the following detailed description taken in conjunction with the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG 1 shows the results of the cell-based assay distinguishing between specific and non-specific PGD2 inhibitors. Compound A000050350 specifically inhibits PGD2 production in RBL cells whereas compound AOOO 127348 non-specifically inhibits both PGD2 and PGE2 production in RBL cells.
FIG 2 is a graph representing the evaluation of cytotoxicity by measuring cell proliferation of rat basophilic leukemia (RBL) cells treated with several concentrations of PGDS test compounds using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a cell-based assay for screening compounds that modulate hematopoietic PGD2 synthase (hPGDS). The assay evaluates potency, specificity and toxicity of test compounds in living cells. The present invention allows for the identification of inhibitor compounds that may be used as drugs to treat many inflammatory diseases including but not limited to asthma, allergic rhinitis, COPD, multiple sclerosis, Alzheimer's disease and other disorders resulting from ischemia-reperfusion injury.
The present invention generally relates to a cell based assay, which is used to measure potency, specificity and cytotoxicity of test compounds that modulate hPGDS activity within a single cell based assay. Measurements can be performed quickly and can be scaled up to test many different compounds simultaneously.
There are no particular restrictions as to the compound that can be assayed. Examples include small molecular weight chemical molecules, libraries of synthetic low molecular compounds, purified proteins, expression products of gene libraries, synthetic peptide libraries, cell extracts and culture supernatants.
Any mammalian cell line may be used in the present invention as long as the mammalian cell line expresses hPGDS. Examples include, but are not limited to, mast cells, antigen-presenting cells, megakaryocytes and Th2 lymphocytes. In addition, mammalian cell lines may be used such as rat basophilic leukemia (RBL). Primary mast cells in different species such as human and mouse, or T cell subtypes in different species are the additional examples. Cells engineered to express or overexpress hPGDS or modified hPGDS are contemplated by the present invention.
The chosen mammalian cells are treated with a stimulatory molecule that enhances arachidonic acid release. Molecules contemplated for use in the present invention are calcium ionophores such as A23187, ionomycin, phorbel esters, growth factors, cytokines, tumor promoters, and calcium channel mobilizer molecules such as BAY K-8644. In another particular embodiment of the present invention, arachidonic acid may be directly added to the chosen mammalian cells. To measure potency in the present invention, cells are treated with a test compound followed by the addition of a stimulatory molecule to enhance arachidonic acid release. Levels of PGD2 production are measured in cells treated with the stimulatory molecule and various concentrations of test compounds. These levels are compared to the levels of PGD2 produced in cells that were treated with stimuli but were not exposed to test compound. The present invention also provides in the same cell-based assay the ability to measure specificity and cytotoxicity. This is designed by evaluating a second readout of prostanoid production, for example, levels of PGE2, in the cell supernatant. If a test compound specifically inhibits hPGDS activity, it will generate an IC50 on PGD2 that is significantly lower than that on PGE2. In contrast, if the test compound is non-specific or cytotoxic, it will generate similar IC50 values for both PGD2 and PGE2. To determine whether the non¬ specific inhibition is due to toxicity of the test compound, an additional cytotoxicity assay may be set up subsequently using the same samples as in the cell-based assay, or separately using the same conditions as the cell-based assay described above. A finding of inhibition of cell proliferation is considered a measurement of off-target activity of the tested compound.
Cytotoxicity assays that may be used in the present invention include but are not limited to assays such as MTS, MTT and LDH assays, all commercially available from Promega, for example.
The ability of a compound to modulate levels of PGD2 is determined, not just by taking measurements in the presence and absence of the inhibitor compound, but also at various concentrations thereof. By taking measurements at various compound concentrations, it is possible to calculate certain features, such as its IC50. An IC50 is defined as the concentration at which the compound produces 50% inhibition. Conversely, the assay of the present invention is easily amendable to assay for compounds that stimulate PGD2 production by using a sub-threshold amount of stimulatory molecule or no stimulatory molecule.
It is also understood that the assay of the present invention may also be conducted as a single point assay evaluating the inhibition of compound on PGD2 and PGE2 production using only one concentration of test compound. Both single point screening and IC50 determinations are amenable to high throughput screening. High throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkington, Mass.; Air Technical Industries, Mentor, Ohio; Beckman Instruments, Inc. Fullerton, Calif.; Precision Systems, Inc., Natick, Mass., etc.). These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final reading of the samples in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for the various high throughput assays. Methods of measuring concentrations of PGD2 and PGE2 are well known in the art.
Examples include high pressure liquid chromatography (HPLC), gas chromatography mass spectrometry (GC-MS), enzyme-linked immunosorbent assay (ELISA), also known as enzyme immunoassay (EIA), radioimmunoassay (RIAs), and fluorescence polarization (FP). The scintillation proximity assay may also be useful in measuring PGD2 and PGE2 levels. The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
All references cited herein are incorporated by reference in their entireties.
EXAMPLES
EXAMPLE 1 : CELL TREATMENT WITH CALCIUM IONOPHORE AND INCUBATION WITH TEST AND CONTROL COMPOUNDS In this example, RBL-2H3 cells (obtained from the American Tissue Culture Center) are trypsmized (0.05% trypsin EDTA in prepared MEM media (Gibco 11095-080) supplemented with 10% fetal bovine serum, L-glutamine, penicillin and streptomycin to a single-cell suspension. RBL cells are plated at 2x104 cells/well in 96 well plates. The plates are incubated overnight at 370C. HBSS buffer (Gibco/Invitrogen 14025-092) is diluted with DMSO (Sigma D-8779) equivalent to the highest concentration of DMSO contained in the reference or test compound. The compound plate(s) and reference control are thawed and mixed well before use. In this example, a COX-I inhibitor SC560 was used as a reference and purchased from Cayman Chemical. Test compound and reference SC560 dilutions are made with a Costar (3960 or equivalent) assay block according to the EIA template shown below. Column 1 wells (Blank, TA=Total activity, NSB=non-specific binding and Bo=background) and columns 2 & 3 are not used for cell treatments, but are filled with standards for the EIA assay. Controls 1, 2, 5 and 6 are positive controls containing calcium ionophore without compound. Controls 3, 4, 7 and 8 are negative controls without calcium ionophore or compound.
Figure imgf000009_0001
Test compounds were diluted as follows: Add 1 ml of HBSS (without DMSO) to assay block wells A4-A10 [30 uM]. Add 620 ul of HBSS w/ 0.3% DMSO to wells B4-B10 through H4-H10. Add 3 ul of compound stock [10 mM] to 30 uM wells. Mix well. Add 310 ul from row A [30 uM] to row B [10 uM]. Mix well. Continue diluting as above, to generate the following concentrations [30, 10, 3.3, 1.1, 0.37, 0.12, 0.04, and 0.014 uM]. The reference SC560 was diluted as follows: Add 1 ml of HBSS (without DMSO) to well All. Add 620 ul of HBSS with 0.3% DMSO to wells B 11 -Hl 1. Add 3 ul of pre-diluted stock [1 niM in 100% DMSO] to well Al 1 [3 uM]. Mix well. Add 310 ul from well Al 1 [3 uM] to well BI l [I uM]. Mix well. Continue diluting to generate the following concentrations [3 uM, 1 uM, 0.33 uM, 0.11 uM, 0.037 uM, 0.012 uM, 0.0041 uM, and 0.0013 uM].
An automated cell treatment for the addition of calcium ionophore (A23187 Sigma #C-7522) and methoximating reagent (prepared according to Cayman kit #512011 directions) was designed using a Zymark SciClone Deck. The present automated (A) protocol requires that a number of steps be performed manually (M) as outlined below.
(A) Remove overnight media and wash Ix with 200 ul HBSS buffer.
Remove HBSS buffer from cells and replace with 200 ul/well diluted compounds and controls according to template. (M) Cover and return cell plates to 37 0C. Incubate for 15 minutes. Uncover cell plates and return to deck. (A) Add 10 ul of 2Ox concentration to 200 ul cell treatments including positive control wells. Note there is no addition of calcium ionophore to negative control wells. (M) Remove empty tip boxes and replace with 200 ul tips at deck locations B2, B3, and B4. (M) Cover and return cell plates to 37 0C. Incubate for 15 minutes. (M) Centrifuge plates @ 1000 x rpm for 5 minutes. Uncover cell plates and return to deck. (A) Collect 25 ul supernatants to be chemically methoximated with 25ul MOX reagent (1 : 1 ratio) according to PGD2-MOX EIA kit (Cayman #512011 or equivalent). See following example. (M) Cover MOX assay plates and incubate @ 60 0C for 30 minutes. (M) Place additional assay plates at deck locations D2, D3, and D4 for supernatants to be collected for PGE2 analysis. (A) Collect 175 ul of remaining supernatant to be evaluated for PGE2. Methoximated (for PGD2) and un-methoximated (for PGE2) supernatants can be stored for up to 3 months @ -80 0C.
EXAMPLE 2: QUANTIFICATION OF PROSTAGLANDIN D2 LEVELS: ENZYME IMMUNOASSAY In this example, the concentration of PGD2 was measured using an enzyme immunoassay (EIA). EIAs for measuring PGD2 are available commercially. For example a PGD2 EIA kits are available from Cayman Chemical. This assay is based on the competition between PGD2-methoxime (MOX) and a PGD2-MOX-acetyleholinesterase (AchE) conjugate (PGD2-M0X tracer) for a limited number of PGD2-M0X- specific rabbit antiserum binding sites. Because the concentration of the PGD2-M0X tracer is held constant while the concentration of PGD2-MOX varies, the amount of PGD2-M0X tracer that is able to bind to the rabbit antiserum will be inversely proportional to the concentration of PGD2-M0X in the well. This rabbit antiserum-PGD2- MOX complex binds to the mouse monoclonal anti-rabbit IgG that has been previously attached to the well. After washing the plate, Ellman's Reagent (which contains the substrate to AchE) is added to the well. The enzymatic product has a distinct yellow color, which absorbs strongly at 412 nm. The intensity of this color is proportional to the amount of
PGD2-MOX tracer bound to the well, which is inversely proportional to the amount of free PGD2-MOX present in the well during the incubation.
The EIA and wash buffers were made according to the commercial instructions. Samples were prepared according to the previous example. Since prostaglandin levels may vary, the supernatants are diluted with EIA buffer to yield prostaglandin levels within the linear range of the standard curve. Commonly used PGD2 dilutions are 1 : 12.5.
The methyl oximating reagent, PGD2-M0X Express EIA standard, PGD2-M0X AchE Express Tracer, PGD2-M0X Express Antiserum and PGD2-M0X Express EIA Methoximating control were prepared according to the manufacturer's instructions. The assay was performed according to the manufacturer's instructions and the plates were read at a wavelength of 412 nm.
After the prostaglandin levels were determined in cells treated with 8 concentrations of test compounds, an IC50 of the compound may be generated by conducting a semi-log plot of the prostaglandin level versus log scale of the compound concentration. This assay can also be conducted as a single point assay evaluating the inhibition of compound on PGD2 production using only one concentration of compound.
EXAMPLE 3: QUANTIFICATION OF PROSTAGLANDIN E2 LEVELS
In this example, the PGE2 concentrations were measured using an enzyme immunoassay (EIA). EIAs for measuring PGE2 are available commercially. For example a PGE2 EIA kit is available from Assay Designs. The PGE2 EIA employs a mouse monoclonal antibody specific for PGE2. The free PGE2 in solution competes with a known amount of PGE2 tracer to bind a limited amount of the anti-PGE2 antibody. The PGE2 tracer is a conjugate of PGE2 and acetylcholinesterase. The anti-PGE2 antibody is then fixed using a goat anti-mouse Ig antibody. The fixed antibody is then developed with Ellman's Reagent, which contains the substrate for acetylcholinesterase. The product produced by this reaction has a yellow color, and absorbs strongly at 412 nm. If there is a high concentration of PGE2, the PGE2 will outcompete the tracer and the resulting sample will have a weak absorbance at 412 nm. Conversely, if there is a low concentration of PGE2, the tracer will outcompete the PGE2 and the resulting sample will have a strong absorbance at 412 nm. In performing this assay, the absorbance at 412 nm was compared to a standard of absorbances at known concentrations of PGE2.
This assay may be easily converted to automated format by one skilled in the art by using a Zymark SciClone Deck, for example.
EXAMPLE 4: QUANTIFICATON OF PGD2 AND PGE2 to distinguish SPECIFIC AND NON-SPECIFIC COMPOUNDS
This example shows how the above PGD2 and PGE2 cell-based assays may be used to distinguish between specific and non-specific compounds. As shown in Figure 1, compound A00050350 generates an IC50 value of 2.65uM relating to PGD2 inhibition, but no inhibition of PGE2 was exhibited, suggesting that A0050350 is a potent and specific inhibitor on PGD2 synthesis. In contrast, compound A000127348 generates similar IC50 values for PGD2 and PGE2; 0.33 uM and 0.41 uM, respectively, suggesting that A000127348 is a non-specific or cytotoxic compound. A subsequent cytotoxicity study confirmed that compound AOOO 127348 affects cell proliferation under the testing conditions.
In this example, RBL cells were treated with the PGDS compounds for 45 min under the same condition as in the cell-based assay except no A23187 was added. The potential cytotoxicity was determined with the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI Cat# G3582). The assay was carried out following the manufacturer's instruction.
Eight concentrations of each compound ranging from 0.0 IuM to 3OuM were determined for cytotoxicity. The testing concentrations were 0.014uM, 0.04IuM, 0.123uM, 0.37OuM, 1.1 HuM. 3.333uM, lOuM and 3OuM (See Figure 2). Compound A000127348 and another PGDS compound, A000123383, were toxic, which are distinguishable from a number of non-toxic test compounds shown in the same plot. Geneticin was used as a positive control.

Claims

CLAIMS What is claimed is:
1. A method for screening for potency, specificity and toxicity of inhibitor compounds of hPGDS in mammalian cells comprising the steps of: i) contacting said mammalian cell with a stimulatory molecule that increases the release of arachidonic acid, ii) treating said mammalian cell with a compound, iii) measuring the level of PGD2 in said mammalian cell or the supernatant, iv) comparing the levels of PGD2 in said mammalian cell to the levels of PGD2 in a control mammalian cell that is not treated with said compound to determine the potency of said compound, v) measuring the level of PGE2 in said mammalian cell vi) comparing the levels of PGD2 with the levels of PGE2 in said mammalian cell " wherein finding the levels of PGD2 is lower than the levels of PGE2 indicate the compound's specific inhibitory activity of hPGDS, vii) measuring the amount of cytotoxicity of compound treated and control mammalian cells and comparing the cytotoxicity levels in treated and control mammalian cells wherein a finding of cytotoxicity in compound treated cells is an indication of inhibition of cell proliferation.
2. The method of claim 1 wherein said mammalian cell is selected from the group consisting of mast cells, antigen-presenting cells, megakaryocytes and TH2 lymphocytes.
3. The method of claim 1 wherein said mammalian cell is a rat basophilic leukemia (RBL).
4. The method of claim 1 wherein said stimulatory molecule is selected from the group consisting of calcium ionophores, ionomycin, phorbel esters, growth factors, cytokines, tumor promoters and calcium channel mobilizer molecules.
5. The method of claim 4 wherein said calcium ionophore is A23187.
6. The method of claim 4 wherein said calcium channel mobilizer molecule is BAY K- 8644.
7. The method of claim 1 wherein said stimulatory molecule is arachidonic acid.
PCT/US2005/026945 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase WO2006015195A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US11/569,146 US20070259384A1 (en) 2004-07-30 2005-07-28 Methods for Determining the Potency, Specificity, and Toxicity of Hematopoietic Prostaglandin D2 Synthase
AU2005267920A AU2005267920A1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin D2 synthase
EP05781699A EP1778860B1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase
JP2007523838A JP2008507980A (en) 2004-07-30 2005-07-28 Method for determining potency, specificity and toxicity of hematopoietic prostaglandin D2 synthase
MX2007000043A MX2007000043A (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase.
DK05781699T DK1778860T3 (en) 2004-07-30 2005-07-28 Method for determining the potency, specificity and toxicity of hemapoietic prostaglandin D2 systasis
DE602005004420T DE602005004420T2 (en) 2004-07-30 2005-07-28 METHOD FOR DETERMINING THE EFFICACY, SPECIFICITY AND TOXICITY OF THE BLOOD-BUILDING PROSTAGLANDIN D2 SYNTHASE
CA002575523A CA2575523A1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase
BRPI0512645-2A BRPI0512645A (en) 2004-07-30 2005-07-28 procedures for determining the potency, specificity and toxicity of hematopoietic prostaglandin d2 synthase
IL180837A IL180837A0 (en) 2004-07-30 2007-01-21 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59250104P 2004-07-30 2004-07-30
US60/592,501 2004-07-30

Publications (2)

Publication Number Publication Date
WO2006015195A1 true WO2006015195A1 (en) 2006-02-09
WO2006015195A8 WO2006015195A8 (en) 2006-12-21

Family

ID=35115717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026945 WO2006015195A1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase

Country Status (15)

Country Link
US (1) US20070259384A1 (en)
EP (1) EP1778860B1 (en)
JP (1) JP2008507980A (en)
KR (1) KR20070046830A (en)
CN (1) CN1993479A (en)
AT (1) ATE384136T1 (en)
AU (1) AU2005267920A1 (en)
BR (1) BRPI0512645A (en)
CA (1) CA2575523A1 (en)
DE (1) DE602005004420T2 (en)
DK (1) DK1778860T3 (en)
ES (1) ES2297753T3 (en)
IL (1) IL180837A0 (en)
MX (1) MX2007000043A (en)
WO (1) WO2006015195A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440417B2 (en) 2008-05-13 2013-05-14 Cayman Chemical Company, Incorporated Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111549000B (en) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 Recombinant adipose-derived stem cell for over-expression of Hpgds, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503674A1 (en) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives
US20040082021A1 (en) * 2002-08-16 2004-04-29 Aventis Pharmaceuticals Inc. Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3600847B2 (en) * 1996-06-05 2004-12-15 財団法人大阪バイオサイエンス研究所 DNA encoding human hematopoietic prostaglandin D synthase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082021A1 (en) * 2002-08-16 2004-04-29 Aventis Pharmaceuticals Inc. Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase
CA2503674A1 (en) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIPOLLONE F ET AL: "Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY 2004 UNITED STATES, vol. 24, no. 7, 20 May 2004 (2004-05-20), pages 1259 - 1265, XP002351016, ISSN: 1079-5642 *
KANAOKA Y ET AL: "HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 69, no. 2/3, 2003, pages 163 - 167, XP009019772, ISSN: 0952-3278 *
MURAKAMI YOUSUKE ET AL: "Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase.", ARTHRITIS AND RHEUMATISM. OCT 2003, vol. 48, no. 10, October 2003 (2003-10-01), pages 2931 - 2941, XP002351017, ISSN: 0004-3591 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440417B2 (en) 2008-05-13 2013-05-14 Cayman Chemical Company, Incorporated Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase

Also Published As

Publication number Publication date
CN1993479A (en) 2007-07-04
DK1778860T3 (en) 2008-05-13
MX2007000043A (en) 2007-03-27
JP2008507980A (en) 2008-03-21
BRPI0512645A (en) 2008-03-25
DE602005004420T2 (en) 2009-01-08
AU2005267920A1 (en) 2006-02-09
CA2575523A1 (en) 2006-02-09
ATE384136T1 (en) 2008-02-15
KR20070046830A (en) 2007-05-03
WO2006015195A8 (en) 2006-12-21
DE602005004420D1 (en) 2008-03-06
ES2297753T3 (en) 2008-05-01
IL180837A0 (en) 2007-06-03
US20070259384A1 (en) 2007-11-08
EP1778860A1 (en) 2007-05-02
EP1778860B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
Zareba-Koziol et al. Stress-induced Changes in the S-palmitoylation and S-nitrosylation of Synaptic Proteins*[S]
Llenado et al. Surfactants
US7081347B2 (en) Method for predicting cardiovascular events
CN110530829A (en) A kind of fluorescence-based early stage drug screening method
Luo et al. Current progress in the detection of adrenergic receptor agonist residues in animal-derived foods
EP1778860B1 (en) Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase
JP2011522265A (en) Protein biomarkers for in vitro testing of developmental and embryonic toxicity of chemicals
WO2008040532A1 (en) Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells
CN1924581A (en) Chemical luminescent analysis reagent kid for prostate specific antigen
De Paoli et al. A rapid GC-MS determination of gamma-hydroxybutyrate in saliva
US7132256B2 (en) Methods for determining the potency, specificity, and toxicity of microsomal prostaglandin E2 synthase
KR20060100423A (en) Quick test for the diagnosis of alzheimer's disease
Arakawa et al. New fluorimetric assay of horseradish peroxidase using sesamol as substrate and its application to EIA
Miller et al. Development of a high-capacity homogeneous fluorescent assay for the measurement of leukotriene B4
Chen et al. Identifying genes that extend life span using a high-throughput screening system
KR20150007701A (en) Biomarkers for detecting hypoxic stress or diagnosing disease related thereto and its uses
MXPA06013354A (en) Methods involving micromosal prostaglandin e2 synthase
CN107208050A (en) Bile in vitro drains determination method
KR20150036838A (en) Markers for detecting adipogenic differentiation of mesenchymal stem cells and its uses
GB2246627A (en) Allergy testing
CN113607707A (en) Rapid marine neurotoxin fluorescence screening method based on sodium ion channel Nav1.1
Sills In vitro screens and functional assays to assess receptor pharmacology
Tsai Immunoassays for the detection of cannabis abuse
CN112384803A (en) Method for determining low and high concentration protein concentration in a single sample
Lavigne et al. A rapid microwell fluorescence immunoassay for cellular protein detection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11569146

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000043

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 180837

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2575523

Country of ref document: CA

Ref document number: 2005267920

Country of ref document: AU

Ref document number: 2007523838

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077002332

Country of ref document: KR

Ref document number: 200580025832.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 425/CHENP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005267920

Country of ref document: AU

Date of ref document: 20050728

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005267920

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005781699

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005781699

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11569146

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2005781699

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512645

Country of ref document: BR